ClinicalTrials.gg

Program

CS-1103

A development code.

Its studies are mostly in Poisoning · Substance-Related Disorders, led by Clear Scientific.

Furthest: phase 2, since Dec 3, 20243 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Clear Scientific30 open or runningphase 2since Dec 3, 2024Mar 5, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 5, 2024First study: phase 1 study in Substance-Related DisordersFirst studyNCT06316973 · 32 enrolled · United States
  2. Dec 3, 2024Phase 2 study in Methamphetamine IntoxicationNCT06721494 · 34 enrolled · United States
  3. Mar 4, 2026Phase 2 study in Fentanyl OverdoseNCT07459166 · 16 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07459166Fentanyl Overdose · United States2CompletedJul 15, 202616
NCT06721494Methamphetamine Intoxication · United States2CompletedOct 24, 202634
NCT06316973Substance-Related Disorders · United States1CompletedMay 30, 202432

How it is read

Names in the registry

  • “CS-1103”, 3 entries

Codes read as this program: CS1103.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.